Novo Nordisk A/S

Novo Nordisk A/S

$87.37
-1.34 (-1.51%)
New York Stock Exchange
USD, DK
Biotechnology

NVO Price Chart

Basic
Market Cap$476.96B
Price$88.5
52 Week Range96.53-148.15
Beta0.17
Margins
Gross Profit Margin84.66%
Operating Profit Margin43.84%
Net Profit Margin35.01%
Valuation (TTM)
P/E Ratio29.27
Price to Sales Ratio9.66
Price to Book Ratio23.01
PEG Ratio5.31

Industry

Biotechnology

Sector

Healthcare

Full-Time Employees

71,880

IPO Date

1981-04-30T00:00:00.000Z

Description

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Phone

45 44 44 88 88

Address

Novo Allé 1, Bagsvaerd, 2880, DK

CIK

0000353278